MAPT and Alzheimer disease: To assess heterogeneity and disease progression reflected by tau lactylation profiles, we observed progressively higher levels of K331 lactylation corresponding to Braak stages (control samples: Braak stages I, II, and III; AD samples: Braak stages IV and V) (Figure 2E).